Related Experiment Videos
The central vasopressinergic system in experimental left ventricular hypertrophy and dysfunction
Frank Muders1, Günter A J Riegger, Udo Bahner
1Klinik und Poliklinik für Innere Medizin II, University of Regensburg, Regensburg, Germany. frank.muders@klinik.uni-regensburg.de
Progress in Brain Research
|November 20, 2002
Summary
Central vasopressin system alterations occur in heart failure models. ACE inhibitors and AT1 receptor antagonists centrally inhibit this system, suggesting new therapeutic targets for cardiovascular diseases.
Area of Science:
- Cardiovascular Physiology
- Neuroendocrinology
Background:
- Cardiac diseases activate neurohormonal systems.
- Central neuropeptide system function in heart failure is poorly understood.
Purpose of the Study:
- Investigate the central vasopressinergic system in a model of myocardial hypertrophy and left ventricular dysfunction.
- Determine the effects of ACE inhibitors and AT1 receptor antagonists on this system.
Main Methods:
- Utilized a rat model of supravalvular aortic stenosis to induce myocardial hypertrophy and left ventricular dysfunction.
- Measured vasopressin concentrations in plasma and specific brain regions.
- Employed autoradiography to assess drug effects.
Main Results:
- Observed altered central vasopressin levels, with differential changes in hypothalamic and brain stem areas.
- Detected reduced vasopressin in the locus coeruleus, potentially inhibiting sympathetic activity.
- Demonstrated central inhibition of the vasopressinergic system by ACE inhibitors and AT1 receptor antagonists.
Conclusions:
- Non-osmotic factors like baroreceptor reflex and angiotensin II stimulate the vasopressinergic system.
- Central effects of ACE inhibitors and AT1 receptor antagonists modulate the vasopressinergic system in heart failure.
- Understanding central mechanisms is vital for developing novel cardiovascular therapies.